Harper Hygienics S.A. (HRP) fair value: what the stock is really worth
As of Oct 13, 2026: fair value of Harper Hygienics S.A. PLN 10.74, price PLN 5.60, upside +91.8%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Harper Hygienics S.A. manufactures and sells hygienic products in Poland and internationally.
Show more
Harper Hygienics S.A. manufactures and sells hygienic products in Poland and internationally. The company offers cotton pads for skin and eyes cleaning and make-up removal, cotton buds, and antibacterial refreshing wet wipes for hands and body; cosmetic buds, intimate hygiene products, and liquids and wipes; disposable wet wipes for infants and children, cosmetic pads, and hygienic buds; wipes for surfaces, including as kitchen, bathroom, windows and mirrors, wooden furniture, anti-electrostatic, and leather furniture; and nail varnish removal pads, as well as period pads, pantyliners, dry wipes, under pads, and cotton balls. It offers its products under the Sweet Sense, Cleanic, Cleanic Kindii, Presto Clean, Nieznost, and Ola brand names, as well as private labels for retail chains. Then company was founded in 1990 and is headquartered in Warsaw, Poland. Harper Hygienics S.A. Is a subsidiary of iCotton SIA.
Stock analysis
Harper Hygienics S.A. (HRP) currently trades at 5.60 PLN, while our model-based Fair Value estimate is 10.74 PLN, implying the stock looks roughly 47.9% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 21.19 PLN per share, and 20 of the 22 models we run sit above the 5.60 PLN price.
Bear case: the Growth DCF group reads lowest at 4.59 PLN, and 2 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: 7.51 PLN (bear) to 20.07 PLN (bull), the price of 5.60 PLN sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Harper Hygienics S.A. reported revenue of 254M PLN in FY2025 versus 260M PLN in FY2021, a compound −0.6%/yr. Reported net income was 7.3M PLN in FY2025.
Key figures
Market cap 35.7M PLN (≈ $9.1M) · P/E ratio 5.5 · P/S ratio 0.16 · EPS (TTM) 1.01 PLN · Net margin 2.9% · Return on equity 13.3% · Return on assets (EBIT) 3.3% · Operating margin 7.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 15% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −28% fair-value upside, at 92%, HRP screens cheaper than that median.
Fair Value models
Bear7.51 PLNFair Value 10.74 PLNBull20.07 PLN
Price 5.60 PLN · Upside +91.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.7942 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings13.00 PLN21.47 PLN37.37 PLN74
EPV7.46 PLN10.65 PLN13.40 PLN73
5Y EBITDA Exit11.05 PLN24.53 PLN42.47 PLN72
All 22 models by family
DCF Models
FCF DCF0.0600 PLN4.26 PLN12.16 PLN69
Owner Earnings13.00 PLN21.47 PLN37.37 PLN74
5Y Revenue Exit5.66 PLN15.36 PLN29.59 PLN68
5Y EBITDA Exit11.05 PLN24.53 PLN42.47 PLN72
5Y P/E Exit1.75 PLN8.71 PLN17.06 PLN65
10Y Revenue Exit2.70 PLN10.70 PLN20.01 PLN62
10Y EBITDA Exit6.56 PLN16.62 PLN28.26 PLN65
10Y P/E Exit0.9700 PLN6.41 PLN11.99 PLN59
Earnings-Based
Graham-Dodd7.78 PLN13.18 PLN16.07 PLN67
EPV7.46 PLN10.65 PLN13.40 PLN73
Multiples
P/E Multiple18.03 PLN24.04 PLN30.05 PLN63
P/S Multiple14.59 PLN19.46 PLN24.32 PLN58
P/B Multiple14.59 PLN19.46 PLN24.32 PLN55
EV/EBIT20.54 PLN31.63 PLN42.72 PLN65
EV/EBITDA22.94 PLN34.83 PLN46.72 PLN66
EV/Revenue11.02 PLN21.19 PLN31.37 PLN51
Asset-Based
NCAV (Graham)5.70 PLN7.64 PLN11.41 PLN54
Growth DCF
Growth DCF0.5100 PLN4.59 PLN11.63 PLN68
Rev-Margin DCF5.66 PLN15.55 PLN27.80 PLN68
Economic Profit
Residual Income9.99 PLN11.00 PLN13.00 PLN71
ROIC Compounder7.46 PLN10.65 PLN14.01 PLN71
Growth Earnings
Growth-Adj P/E12.73 PLN18.18 PLN23.64 PLN67
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+11.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Start year 2020 (pandemic). Over 10 years: +2.5% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+37.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+37.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.12.0% vs −13.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 7%
2025 sits 166% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about +17.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 240 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside+91.8% · Top 25%
Profitability
Return on equity (TTM)13.3% · Above median
Return on assets4.8% · Above median
Net margin (TTM)3.7% · Below median
Operating margin (TTM)7.0% · Below median
Growth and dividend
Revenue growth8.7% · Above median
Balance sheet
Debt / equity1.13× · Highest 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Harper Hygienics S.A. (HRP) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 10.74 PLN versus a price of 5.60 PLN, about +92% upside (undervalued).
What is the fair value of HRP?
Our model-based fair value for Harper Hygienics S.A. is 10.74 PLN (as of Oct 3, 2026), built from audited fundamentals. The current price: 5.60 PLN.
What is the quality score of HRP?
Harper Hygienics S.A. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Harper Hygienics S.A. (HRP)?
Our model-based price target is the fair value of 10.74 PLN (as of Oct 3, 2026) from 22 valuation models. Cautious scenario 7.51 PLN, optimistic scenario 20.07 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Harper Hygienics S.A. stock forecast for 2026?
Our models put fair value at 10.74 PLN, about +92% upside versus a price of 5.60 PLN (undervalued). Cautious scenario 7.51 PLN, optimistic scenario 20.07 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Harper Hygienics S.A. (HRP)?
Harper Hygienics S.A. reported trailing-twelve-month revenue of about 262M PLN (latest available figure, as of Oct 3, 2026).
What growth is priced into Harper Hygienics S.A. (HRP)?
For today's price to be fair in a discounted-cash-flow model, Harper Hygienics S.A. would have to grow free cash flow by +20.7 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.8 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of HRP use?
Our models discount Harper Hygienics S.A. at 9.5 %: a base by market capitalisation (nano), damped by beta 0.58, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Harper Hygienics S.A. that is +20.7 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Harper Hygienics S.A. (HRP) delivered so far?
Over the past 5 years revenue at Harper Hygienics S.A. grew +1.8 % a year. The price currently implies +20.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Harper Hygienics S.A. (HRP) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Harper Hygienics S.A. (+20.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Harper Hygienics S.A. (HRP)?
The free-cash-flow yield on the price is 8.70 %: that much free cash flow Harper Hygienics S.A. produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Harper Hygienics S.A. (HRP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Harper Hygienics S.A. it is 10.74 PLN per share (as of Oct 3, 2026), against a price of 5.60 PLN. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Harper Hygienics S.A. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, HRP trades below its calculated fair value: price 5.60 PLN, fair value 10.74 PLN, a gap of about +92% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HRP?
No. The price is what the market pays today (5.60 PLN); the fair value is what the company's own numbers justify (10.74 PLN). For Harper Hygienics S.A. the two are 5.14 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Harper Hygienics S.A. worth?
The market values Harper Hygienics S.A. at about 35.7M PLN (market capitalisation, as of Oct 3, 2026). Per share that is 5.60 PLN; our models calculate a fair value of 10.74 PLN per share.
What do the bullish and bearish scenarios say about HRP?
Our models span a range for Harper Hygienics S.A.: cautious scenario 7.51 PLN, base 10.74 PLN, optimistic 20.07 PLN per share (as of Oct 3, 2026, price 5.60 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HRP?
Harper Hygienics S.A. trades at a price-to-earnings ratio of 5.5 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 10.74 PLN is built from several models across several years. Other multiples: P/B 0.5, P/S 0.1, EV/EBITDA 4.5.
How solid is the balance sheet of Harper Hygienics S.A. (HRP)?
Balance-sheet figures for Harper Hygienics S.A. (as of Oct 3, 2026): return on equity 13.3%, debt of 1.13 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is HRP from its 52-week high?
Harper Hygienics S.A. trades at 5.60 PLN, about 8% below its 52-week high of 6.12 PLN and 15% above the low of 4.89 PLN (as of Oct 13, 2026). Distance from the high says nothing about value: that is what the fair value of 10.74 PLN is for.
Which stocks are comparable to Harper Hygienics S.A.?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, The Estée Lauder Companies Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Harper Hygienics S.A. stock attractive at the current price?
The data as of Oct 3, 2026: price 5.60 PLN, calculated fair value 10.74 PLN (+92%), Quality Score 53/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HRP calculated?
We run Harper Hygienics S.A. through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10.74 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Harper Hygienics S.A. currently trades 48 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Harper Hygienics S.A. (HRP)?
The closing price on Oct 13, 2026 was 5.60 PLN. Our model-based fair value is 10.74 PLN, about +92% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Harper Hygienics S.A. right now?
The price is below even our cautious bear case (7.51 PLN). The market is more pessimistic than our downside scenario. The model range is unusually wide (7.51 PLN to 20.07 PLN). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Harper Hygienics S.A.
How large is the market capitalisation of Harper Hygienics S.A. (HRP)?
The market capitalisation of Harper Hygienics S.A. is 35.7M PLN (≈ $9.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Harper Hygienics S.A. (HRP)?
The price-to-sales ratio of Harper Hygienics S.A. is 0.16 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Harper Hygienics S.A. (HRP)?
Earnings per share at Harper Hygienics S.A. are 1.01 PLN (price ÷ EPS = P/E 5.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Harper Hygienics S.A. (HRP)?
The net margin of Harper Hygienics S.A. is 2.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Harper Hygienics S.A. (HRP)?
The return on equity (ROE) of Harper Hygienics S.A. is 13.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Harper Hygienics S.A. (HRP)?
On an EBIT basis the return on assets of Harper Hygienics S.A. is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Harper Hygienics S.A. (HRP)?
The operating margin of Harper Hygienics S.A. is 7.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Harper Hygienics S.A. (HRP)?
Revenue at Harper Hygienics S.A. is growing +8.7% versus a year earlier (3y avg −2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Harper Hygienics S.A. (HRP)?
Earnings per share at Harper Hygienics S.A. are growing −24.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Harper Hygienics S.A. (HRP) carry?
The net debt of Harper Hygienics S.A. is 81.0M PLN (fiscal year 2025, ≈ 26.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Harper Hygienics S.A. in the live analysis
One click puts Harper Hygienics S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
